Hemophilia Treatment Market Research Report - Forecast to 2027

Hemophilia Treatment Market Research Report: By Type (Hemophilia A, Hemophilia B, Hemophilia C), By Treatment (Recombinant Coagulation Factor, Plasma-Derived Coagulation Factor, Desmopressin, Antifibrinolytic Agents), End User Forecast Till 2027

ID: MRFR/Pharma/4233-CR | October 2018 | Region: Global | 158 pages

Hemophilia Treatment Market Overview: 


Hemophilia Treatment market will exhibit an above-average CAGR of 6.10% during 2018 to 2023.


Hemophilia is a genetic disorder that is generally hereditary where the patient’s blood lacks the required proteins that help in blood coagulation. The condition could be mild, moderate, and severe. However, the condition is generally diagnosed at the early stages in patients. A recent report says that over 400 babies are born with hemophilia each year and over 33,000 males were living with the condition in the United States. The early diagnosis of the condition is made possible since most of the babies born are tested immediately after they are born. Prenatal genetic testing is carried out for the fetuses inside the womb which helped to diagnose the condition.  


Due to the absence of a sufficient amount of blood-clotting proteins and factors, clotting of blood becomes difficult for the patients. The males possessing the condition are because of the X chromosome passed to them from their mother. The prevalent treatment given to hemophilia is Replacement therapy through which the missing protein, generally clotting factor VIII is administered into patients’ veins. For the patients who are diagnosed with a severe condition of Hemophilia, the major reasons are the presence of other rare complications of the condition and other health conditions. 


COVID 19 Analysis: 


The outbreak of COVID 19 has affected a huge population all over the globe. However, the people who are diagnosed with Hemophilia are very much prone to infectious diseases. Period before COVID also, the blood-borne viruses have severely targeted the Hemophilia patients. Hemophilia patients are advised to monitor their blood pressure and follow medical guidelines to ensure a good immune system. Hence the pandemic has increased the Hemophilia Treatment market value. 


In December 2020, four associations namely the World Federation of Hemophilia (WFH), the European Association for Hemophilia and Allied Disorders (EAHAD), European Hemophilia Consortium (EHC), and U.S. National Hemophilia Foundation (NHF) have combined and issued COVID vaccination guidelines for the Hemophilia patients which have also recommended to continue the treatment for Hemophilia after the COVID vaccination. Such constant guidance and recommendations have enhanced the Hemophilia Treatment market outlook during the pandemic. 


Market dynamics: 


Market drivers:


The increasing number of Hemophilia cases across the globe has been the primary factor that fuels the Hemophilia Treatment industry growth. In the year 2019, there were over 49,083 people diagnosed with bleeding disorders which have increased to 400,000 people in the year 2020-2021. Additionally, favorable government schemes in several countries like reducing the expenditure related to Hemophilia Treatment have impacted the market growth. 


The varied availability of therapies and medications has increased the demand for the Hemophilia Treatment market growth. Therapy of inhibitors, home therapy, free factor replacement, Antifibrinolytic medicines, gene therapy, and physical therapy are some of the commonly utilized therapies and medications used in Hemophilia treatment. These factors have created a huge positive impact on the Hemophilia Treatment market growth. 


Market opportunities: 


The increasing governmental schemes and aggressive campaigning has aided the growth of the Hemophilia Treatment market in recent years. Especially the medical guidelines according to the COVID vaccination has enhanced the treatment and facilities related to Hemophilia Treatment in recent years. The injectable administration is showcasing a growth rate of over 5% in recent years, owing to the increased life quality and enhance overall treatment witnessed in Hemophilia patients. 


The recent technologies and medications have created a revolution in the Hemophilia Treatment market outlook in recent years. Recent inventions have shown up to 80% of recovery from the symptoms of the condition and over 94% reduction in the annual bleeding rates. These factors have created a major opportunity for the Hemophilia Treatment industry growth. 


Market restraints: 


The higher costs associated with the recombinant products and the complications involved in the replacement therapies are currently hindering the growth of the Hemophilia Treatment industry.


Hemophilia patients who undergo the replacement therapies acquire complications like viral infections like hepatitis B and C or HIV. These adverse actions on treating the condition have impacted the growth of the Hemophilia Treatment industry.


The patients are capable of developing inhibitors that destroy the injected clotting factor before they start to work. The chances of developing these inhibitors in the patients with Severe Hemophilia A range between 20-30% and the chances in patients with hemophilia B ranges between 2-5%. These factors have also impacted the growth of the Hemophilia treatment industry. 


Market challenges: 


The increasing costs of the recombinant products and the overall treatment are considered as the primary challenge for the growth of Hemophilia treatment in recent years. The higher investment requirements in the R&D development and manufacturing processes are the primary reasons for the increasing costs of the treatment. 


Some of the therapies like gene therapy are yet to be approved for treating Hemophilia. The delays in the researches in the clinical trials are also imposing challenges for the growth of the Hemophilia Treatment market. 


Cumulative growth analysis: 


The recombinant coagulation factor concentrates have dominated the market with 52.91% in the year 2020. The growing research activities in gene therapies and various other methods are significantly increasing the demand for the Hemophilia Treatment market growth. The increasing government incentives towards the market and aggressive campaigns have also aided the growth of the Hemophilia Treatment industry. 


The Hemophilia Treatment industry registering a CAGR of 6.10% in the forecast period. The rising number of cases where bleeding occurs in joints has impacted the growth of the market in recent years. Joint bleeding is considered the major challenge in the market, owing to the higher chances of permanent damage of knee, ankle, or elbow joints. The development of inhibitors that slashes the efficacy of administrating drugs and medications is also becoming a major challenge in the Hemophilia Treatment industry in recent years. 


Value chain analysis: 


Hemophilia is a bleeding disorder that occurs if the individual’s blood clotting mechanism is damaged. The recent reports state that one in 5000 males are born with Hemophilia in the US, however, the poor economic condition of the country highly affects the treatment and access to the facility. A recent study shows that over 75% of Hemophilia patients are unable to access the treatments, due to which over 60% of patients are developing severity of the condition.  


Increasing awareness towards home therapies, effective precautions, and physical therapies have reduced the severity of the condition in several Hemophilia cases. Additionally, the inventions in the treatments and methodologies have increased the Hemophilia treatment market value in recent years. 


Segment overview: 


Based on diagnosis: 



  • Replacement therapy

  • Gene Therapy 


Based on treatment: 



  • Plasma-derived coagulation factor concentrate

  • Recombinant Coagulation Factor Concentrates

  • Desmopressin

  • Antifibrinolytic agents

  • Gene therapy 


Based on the product: 



  • Plasma-derived coagulation factor concentrates





      • Factor VIII

      • Factor IX

      • Factor XIII

      • Activated Prothrombin complex concentrate

      • Von Willebrand factor



  • Recombinant coagulation factor concentrates



      • Factor VIII

      • Factor IX

      • Von willebrand factor



  • Desmopressin

  • Antifibrinolytic agents 


Based on distribution channel:



  • Hospital pharmacy

  • Retail pharmacy

  • Others 


Regional analysis: 


Currently, North America is handling the Hemophilia treatment strategies better by increasing its partnerships and collaborations with leading market players. These strategies have impacted the market growth positively. Additionally, increasing awareness of the condition and the technological advances in the products and therapeutic methods have further fueled the growth of the Hemophilia treatment market in recent years in North America. 


Association of America has expanded its market growth by offering co-pay initiatives for the patients to acquire continuous treatment. Recently, the advancements in gene therapy that targets coagulation factors have impacted a huge impact on the Hemophilia treatment industry. Asia-pacific is expected to hold the second-largest position in the Hemophilia Treatment market outlook because of the increasing favorable reimbursement policies. Stats of China has declared that over 80% of the Hemophilia treatment done in the region has been covered under health insurance which accounted for more than USD 16,000 in the year 2012. Since then the favorable schemes have been rising in China. 


Competitive landscape: 



  • Takeda Pharmaceutical Co., Ltd.,

  • Sanofi S.A., Octapharma AG

  • Swedish Orphan Biovitrum AB

  • Baxter International Inc.

  • Biogen Inc.

  • Bayer AG

  • CSL Behring

  • Ferring B.V.

  • Pfizer, Inc.

  • Kedrion

  • Novo Nordisk A/S

  • F. Hoffmann-La Roche AG. 


Recent developments: 


Hemophilia Treatment has generally integrated the coagulation factor into the patients. The recent development of a lab version of coagulation factor VIII which is named as GreenGene F (beroctocog alfa) has gotten approval from the Chinese regulators. This coagulation factor is expected to be administrated into the patients’ by 2022 for control and prevention of Hemophilia A.  


The existing technology in liver transplantation and treating liver impairment has been recently utilized in Hemophilia treatment. The Hepastem technology which grows live cells in the healthy liver of the donor, which are then injected into the patients, is expected to make a huge difference in patients diagnosed with Hemophilia A and Hemophilia B where the gene therapy seems to be less effective.  


Report overview: 


This report has covered: 



  • Market overview

  • COVID -19 Analysis

  • Market dynamics

  • Cumulative growth analysis

  • Value chain analysis

  • Segment overview

  • Regional analysis

  • Competitive landscape

  • Recent developments 


Segmentation Table: 


Based on diagnosis: 



  • Replacement therapy

  • Gene Therapy 


Based on treatment: 



  • Plasma-derived coagulation factor concentrate

  • Recombinant Coagulation Factor Concentrates

  • Desmopressin

  • Antifibrinolytic agents

  • Gene therapy 


Based on the product: 



  • Plasma-derived coagulation factor concentrates





      • Factor VIII

      • Factor IX

      • Factor XIII

      • Activated Prothrombin complex concentrate

      • Von Willebrand factor



  • Recombinant coagulation factor concentrates



      • Factor VIII

      • Factor IX

      • Von willebrand factor



  • Desmopressin

  • Antifibrinolytic agents 


Based on distribution channel:



  • Hospital pharmacy

  • Retail pharmacy

  • Others


 



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   6.10% (2018-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   F.Hoffmann-La Roche Ltd, Octapharma, CSL Behring, Kedrion, Sanofi, Bayer AG, Baxter, Swedish Orphan Biovitrum AB, Grifols International S.A, Shire, Pfizer Inc, and Novo Nordisk A/S.
  Key Market Opportunities   Joint ventures, strategic alliances, mergers and acquisitions, new product developments
  Key Market Drivers   Increased prevalence of the disease has fueled the demand for various hemophilia treatment modules


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :


Global Hemophilia Treatment Market was valued at USD 11.2 billion in 2017.

The market is expected to exhibit a strong 6.1% CAGR over the forecast period from 2020 to 2027.

Growing advances in recombinant cell development are likely to be a major driver for the Hemophilia Treatment Market.

The leading type of hemophilia is hemophilia A, which held a share of 78.7% in the market in 2017.

Leading players in the Hemophilia Treatment Market include Octapharma, Sanofi, and Bayer, among others.

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Hemophilia Market, by Type

6.1 Introduction

6.2 Hemophilia A

6.2.1 Market Estimates & Forecast, 2020 – 2027

6.3 Hemophilia B

6.3.1 Market Estimates & Forecast, 2020 – 2027

6.4 Hemophilia C

6.4.1 Market Estimates & Forecast, 2020 – 2027

6.5 Others

6.5.1 Market Estimates & Forecast, 2020 – 2027

Chapter 8. Global Hemophilia Market, by treatment

8.1 Introduction

8.2 Recombinant coagulation factor concentrates

8.2.1 Market Estimates & Forecast, 2020 – 2027

8.3 Plasma-derived coagulation factor concentrates

8.3.1 Market Estimates & Forecast, 2020 – 2027

8.4 Desmopressin

8.4.1 Market Estimates & Forecast, 2020 – 2027

8.5 Antifibrinolytic Agents

8.5.1 Market Estimates & Forecast, 2020 – 2027

Chapter 9. Global Hemophilia Market, by End Users

9.1 Introduction

9.2 Hospitals

9.2.1 Market Estimates & Forecast, 2020 – 2027

9.3 Clinics

9.3.1 Market Estimates & Forecast, 2020 – 2027

9.4 Diagnostic Centers

9.4.1 Market Estimates & Forecast, 2020 – 2027

9.5 Drug Stores

9.5.1 Market Estimates & Forecast, 2020 – 2027

9.6 Pharmacies

9.6.1 Market Estimates & Forecast, 2020 – 2027

9.7 Others

9.7.1 Market Estimates & Forecast, 2020 – 2027

Chapter 10. Global Hemophilia Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 U.S.

10.2.1.1 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

Chapter 11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 Baxter International, Inc.

12.1.1 Company Overview

12.1.2 Types Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 Bayer AG

12.2.1 Company Overview

12.2.2 Types Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Biogen

12.3.1 Company Overview

12.3.2 Types Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 CSL Ltd.

12.4.1 Company Overview

12.4.2 Types/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 GENENTECH

12.5.1 Company Overview

12.5.2 Types Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 GENENTECH Private Limited

12.6.1 Company Overview

12.6.2 Types Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 NOVO NORDISK

12.7.1 Overview

12.7.2 Types Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Hemophilia industry

Chapter 14 Appendix

LIST OF TABLES

Table 1 Hemophilia Industry Synopsis, 2020 – 2027

Table 2 Hemophilia Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Hemophilia Market by Region, 2020 – 2027, (USD Million)

Table 4 Hemophilia Market by Type, 2020 – 2027, (USD Million)

Table 5 Hemophilia Market by Treatment, 2020 – 2027, (USD Million)

Table 6 Hemophilia Market by End User, 2020 – 2027, (USD Million)

Table 7 North America Hemophilia Market by Type, 2020 – 2027, (USD Million)

Table 8 North America Hemophilia Market by Treatment, 2020 – 2027, (USD Million)

Table 9 North America Hemophilia Market by End User, 2020 – 2027, (USD Million)

Table 10 US Hemophilia Market by Type, 2020 – 2027, (USD Million)

Table 11 US Hemophilia Market by Treatment, 2020 – 2027, (USD Million)

Table 12 US Hemophilia Market by End User, 2020 – 2027, (USD Million)

Table 13 Canada Hemophilia Market by Type, 2020 – 2027, (USD Million)

Table 14 Canada Hemophilia Market by Treatment, 2020 – 2027, (USD Million)

Table 15 Canada Hemophilia market by End User, 2020 – 2027, (USD Million)

Table 16 South America Hemophilia Market by Type, 2020 – 2027, (USD Million)

Table 17 South America Hemophilia Market by Treatment, 2020 – 2027, (USD Million)

Table 18 South America Hemophilia Market by End User, 2020 – 2027, (USD Million)

Table 19 Europe Hemophilia Market by Type, 2020 – 2027, (USD Million)

Table 20 Europe Hemophilia Market by Treatment, 2020 – 2027, (USD Million)

Table 21 Europe Hemophilia Market by End User, 2020 – 2027, (USD Million)

Table 22 Western Europe Hemophilia Market by Type, 2020 – 2027, (USD Million)

Table 23 Western Europe Hemophilia Market by Treatment, 2020 – 2027, (USD Million)

Table 24 Western Europe Hemophilia Market by End User, 2020 – 2027, (USD Million)

Table 25 Eastern Europe Hemophilia Market by Type, 2020 – 2027, (USD Million)

Table 26 Eastern Europe Hemophilia Market by Treatment, 2020 – 2027, (USD Million)

Table 27 Eastern Europe Hemophilia Market by End User, 2020 – 2027, (USD Million)

Table 28 Asia Pacific Hemophilia Market by Type, 2020 – 2027, (USD Million)

Table 29 Asia Pacific Hemophilia Market by Treatment, 2020 – 2027, (USD Million)

Table 30 Asia Pacific Hemophilia market by End User, 2020 – 2027, (USD Million)

Table 31 The Middle East & Africa Hemophilia Market by Type, 2020 – 2027, (USD Million)

Table 32 The Middle East & Africa Hemophilia Market by Treatment, 2020 – 2027, (USD Million)

Table 33 The Middle East & Africa Hemophilia market by End User, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Hemophilia Market

Figure 3 Segmentation Market Dynamics for Hemophilia Market

Figure 4 Global Hemophilia market Share, by Type 2020

Figure 5 Global Hemophilia market Share, by Treatment 2020

Figure 6 Global Hemophilia market Share, by End User, 2020

Figure 7 Global Hemophilia market Share, by Region, 2020

Figure 8 North America Hemophilia market Share, by Country, 2020

Figure 9 Europe Hemophilia market Share, by Country, 2020

Figure 10 Asia Pacific Hemophilia market Share, by Country, 2020

Figure 11 Middle East & Africa Hemophilia market Share, by Country, 2020

Figure 12 Global Hemophilia market: Company Share Analysis, 2020 (%)

Figure 13 Baxter International, Inc.: Key Financials

Figure 14 Baxter International, Inc. Segmental Revenue

Figure 15 Baxter International, Inc. : Geographical Revenue

Figure 16 Bayer AG: Key Financials

Figure 17 Bayer AG: Segmental Revenue

Figure 18 Bayer AG: Geographical Revenue

Figure 19 Biogen: Key Financials

Figure 20 Biogen: Segmental Revenue

Figure 21 Biogen: Geographical Revenue

Figure 22 CSL Ltd.: Key Financials

Figure 23 CSL Ltd.: Segmental Revenue

Figure 24 CSL Ltd.: Geographical Revenue

Figure 25 GENENTECH: Key Financials

Figure 26 GENENTECH: Segmental Revenue

Figure 27 GENENTECH Geographical Revenue

Figure 28 GENENTECH Private Limited: Key Financials

Figure 29 GENENTECH Private Limited: Segmental Revenue

Figure 30 GENENTECH Private Limited: Geographical Revenue

Figure 31 NOVO NORDISK: Key Financials

Figure 32 NOVO NORDISK: Segmental Revenue

Figure 33 NOVO NORDISK: Geographical Revenue